Skip to main content

Articles

Page 1 of 71

  1. Atogepant, the first oral CGRP receptor antagonist approved for migraine prevention, has demonstrated efficacy and safety in randomized clinical trials (RCT). However, prospective real-world data are lacking.

    Authors: Piero Barbanti, Gabriella Egeo, Francesca Pistoia, Cinzia Aurilia, Paola Scatena, Steno Rinalduzzi, Silvia Strumia, Antonio Salerno, Fabio Frediani, Andrea Galli, Massimo Autunno, Laura Di Clemente, Maurizio Zucco, Maria Albanese, Francesco Bono, Pietrantonio Bruno…
    Citation: The Journal of Headache and Pain 2025 26:122
    Content type: Research Published on:

  2. Transvenous Onyx embolization of cerebrospinal fluid-venous fistulas (CSFVF) is an emerging and effective treatment for symptomatic spontaneous intracranial hypotension (SIH). This condition significantly impa...

    Authors: Malo Goapper, Liesjet E.H. van Dokkum, Vincent Costalat, Gaetano Risi, Lucas Corti, Olivia Portalier, Nicolas Lonjon, Emmanuelle Le Bars, Anne Ducros and Federico Cagnazzo
    Citation: The Journal of Headache and Pain 2025 26:120
    Content type: Research Published on:

  3. The neuropeptides calcitonin gene-related peptide (CGRP) and substance P are important mediators of neurogenic inflammation when they are released from activated primary nociceptive afferents. It is long evide...

    Authors: Mária Dux and Karl Messlinger
    Citation: The Journal of Headache and Pain 2025 26:119
    Content type: Research Published on:

  4. This study updates data on migraine prevalence in Spain, examining regional variations, healthcare resource utilization (HCRU), and patient-reported outcomes (PROs).

    Authors: Margarita Sanchez-del-Rio, David García-Azorín, Carmen Peral, Beatriz Armada, Pablo Irimia-Sieira and Jesus Porta-Etessam
    Citation: The Journal of Headache and Pain 2025 26:117
    Content type: Research Published on:

  5. Neuropathic pain is a chronic condition with limited effective treatments, closely associated with astrocytes and their role in central sensitization. Apolipoprotein E (ApoE), predominantly expressed in astroc...

    Authors: Kaiming Yu, Xiongyao Zhou, Baolong Li, Jialu Sun, Tuo Yang, Weizhen Li, Ningning Wang, Xiaosong Gu, Shusen Cui and Rangjuan Cao
    Citation: The Journal of Headache and Pain 2025 26:116
    Content type: Research Published on:

  6. The pathophysiological mechanism of migraine remains elusive, thereby impeding the effective treatment of the disease. Current neuroimaging research focuses on changes in brain functional connectivity, functio...

    Authors: Zhilei Li, Yanliang Mei, Lei Wang, Tianhua Fan, Cheng Peng, Kaibo Zhang, Shouyi Wu, Tong Chen, Zhenchang Zhang, Binbin Sui, Yonggang Wang and Xueying Yu
    Citation: The Journal of Headache and Pain 2025 26:115
    Content type: Research Published on:

  7. Migraine is a prevalent debilitating neurological illness that stands among the top causes of disability and significantly impacts the quality of life. Migraine-related functional impairment involves physical,...

    Authors: Ahmed Amir Samir, Ahmed W. Hageen, Ahmed Elgammal, Mostafa Meshref, Mennatullah A. El-Refaay, Mohamed Medhat Taalap, Ali Elsaeed Nassef, Rawan Ali Bedewe, Ahmed Almeldein and Ibrahim Ali Kabbash
    Citation: The Journal of Headache and Pain 2025 26:114
    Content type: Research Published on:

  8. We read with great interest the recent publication by Marston and colleagues in Nature Medicine, entitled “Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive gr...

    Authors: Linda Al-Hassany, Ruben W. A. van Drie, Deirdre M. Boucherie and Antoinette MaassenVanDenBrink
    Citation: The Journal of Headache and Pain 2025 26:113
    Content type: Correspondence Published on:

    The original article was published in Nature Medicine 2025 31:s41591-025-03533-w

  9. Increasing endocannabinoids (endoCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), through inhibition of the degrading hydrolase enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (...

    Authors: Georgii Krivoshein, Adriana Della Pietra, Juha Savinainen, Arn M. J. M. van den Maagdenberg and Rashid Giniatullin
    Citation: The Journal of Headache and Pain 2025 26:112
    Content type: Research Published on:

  10. Authors: Flavia Brugia, Konstantin Ivanov, Auni Aroviita, Raisa Giniatullina, Marko Lehtonen, Tarja Malm, Juha Savinainen, Rashid Giniatullin and Adriana Della Pietra
    Citation: The Journal of Headache and Pain 2025 26:111
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2025 26:85

  11. Migraine is a complex neurological disorder frequently associated with hypothalamic dysfunction. This brain region is essential for maintaining homeostasis due to its regulation of autonomic, endocrine, and ci...

    Authors: Ana Belen Salinas-Abarca, Mohammed Gamal-Eltrabily, Marcela Romero-Reyes and Simon Akerman
    Citation: The Journal of Headache and Pain 2025 26:110
    Content type: Review Published on:

  12. The present study aimed to deliver a replicable transcriptomic map of migraine without aura (MO) and its comprehensive, genome- and drug discovery focused analysis to identify hypotheses for future research- a...

    Authors: Peter Petschner, Sahel Kumar, Duc A. Nguyen, Dora Torok, Zsofia Gal, Daniel Baksa, Kinga Gecse, Gyongyi Kokonyei, Hiroshi Mamitsuka and Gabriella Juhasz
    Citation: The Journal of Headache and Pain 2025 26:109
    Content type: Research Published on:

  13. Trigeminal activation and sensitisation involved in chronic inflammatory orofacial pain share several similarities with headaches, including migraine. Therefore, understanding the pathophysiological mechanisms...

    Authors: Krisztina Takács-Lovász, Timea Aczél, Violetta Mohos, Máté Harmath, Jennet Pirkuliyeva, Gellért Karvaly, Róbert Farkas, Michal Ciborowski, Joanna Godzien, Kata Bölcskei, József Kun and Zsuzsanna Helyes
    Citation: The Journal of Headache and Pain 2025 26:108
    Content type: Research Published on:

  14. People with migraine may prefer over-the-counter (OTC) drugs because of multiple reasons, but their overuse can cause medication overuse headaches. This analysis of the ObserVational survey of the Epidemiology...

    Authors: Ryotaro Ishii, Tsubasa Takizawa, Shiho Suzuki, Daisuke Danno, Moemi Miura, Yoshinori Tanizawa, Satoshi Osaga, Chie Hashimoto and Mika Komori
    Citation: The Journal of Headache and Pain 2025 26:107
    Content type: Research Published on:

  15. We have previously shown headache to be highly prevalent in Delhi and National Capital Region of northern India, as we did earlier in Karnataka State in the south. Here we present a complementary study perform...

    Authors: Anand Krishnan, Debashish Chowdhury, Ashish Duggal, Ritvik Amarchand, Andreas Husøy and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2025 26:106
    Content type: Research Published on:

  16. The monoamine system, particularly the serotonergic neurons in the dorsal raphe nucleus (DRN), associated with the synthesis and release of 5-hydroxytryptamine, is crucial for regulating pain. The lateral habe...

    Authors: Yanfei Sun, Jing Cao, Chunpeng Xu, Jiangtao Sun, Xiaofeng Liu, Zhenguang Shi, SiMeng An, Danyang Zhao, Dongjie Sun, Xuxin Wang, Guoyan Zhao, Chi Zhang, Guangjian Li, Jinyu Xiao, Jing Yang and Hua Zhao
    Citation: The Journal of Headache and Pain 2025 26:105
    Content type: Research Published on:

  17. Migraine is a leading cause of disability worldwide, significantly impacting quality of life and healthcare systems. Despite its high prevalence and burden, migraine remains underprioritized in global health p...

    Authors: Yun-Xia Wang, Guang-Shuang Lu, Jin-Jing Zhao, Wei Dai, Na Zheng, Guo-En Yao and Ruo-Zhuo Liu
    Citation: The Journal of Headache and Pain 2025 26:104
    Content type: Research Published on:

  18. Migraine ranks as the second-leading cause of global neurological disability, affecting approximately 1.1 billion individuals worldwide with severe quality-of-life impairments. Although adjustable risk factors...

    Authors: Yu-Chen Liu, Ye-Hai Liu, Hai-Feng Pan and Wei Wang
    Citation: The Journal of Headache and Pain 2025 26:103
    Content type: Research Published on:

  19. Migraine is a common comorbidity with fibromyalgia (FM). CGRP is a potent inflammatory neuropeptide that may play a role in somatic and visceral pain either inflammatory or neuropathic. Previous studies have r...

    Authors: Marina de Tommaso, Stefania Scannicchio, Giulia Paparella, Livio Clemente and Giuseppe Libro
    Citation: The Journal of Headache and Pain 2025 26:102
    Content type: Research Published on:

  20. The exact mechanisms that trigger the activation of the trigeminovascular system in migraine remain unclear. The involvement of calcitonin gene-related peptide (CGRP) in migraine is well-documented, and treatm...

    Authors: Fahimeh Martami and Kathleen F. Holton
    Citation: The Journal of Headache and Pain 2025 26:101
    Content type: Review Published on:

  21. In the sustainable development goals (SDG) context of seeking universal health coverage, the expanding gap between the supply of specialized and primary health-care providers of headache-related health care an...

    Authors: Heba BaniHani, Christian Lampl, Antoinette MaassenvandenBrink, Faisal Mohammad Amin, Louise Ninett Carlsen, Gianluca Coppola, Christina Deligianni, Raquel Gil-Gouveia, Philip R. Holland, Andreas K. Husøy, Rigmor Jensen, Madalena Plácido, Uwe Reuter, Kristina Ryliškienė, Margarita Sanchez del Río, Henrik Winther Schytz…
    Citation: The Journal of Headache and Pain 2025 26:100
    Content type: Consensus Article Published on:

  22. The use of monoclonal antibodies targeting Calcitonin Gene-Related Peptide (CGRP) is an established treatment for chronic migraine (CM). However, its efficacy in CM patients with medication overuse headache (M...

    Authors: Nhan Nguyen, Vinh Ho Quang Tri, Vy Nguyen Ngoc Dan, Nghi Bao Tran, Laszlo Olah and Mate Heja
    Citation: The Journal of Headache and Pain 2025 26:99
    Content type: Research Published on:

  23. Resistance to treatments have been assessed in chronic conditions such as migraine, but not in temporomandibular disorders (TMD). This study aimed to identify factors that influence treatment outcome in patien...

    Authors: Giancarlo De la Torre Canales, Rodrigo Lorenzi Poluha, Flávia Fonseca Carvalho Soares, Dyna Mara Araújo Oliveira Ferreira, Alfonso Sánchez-Ayala, Leonardo Rigoldi Bonjardim, Malin Ernberg and Paulo César Rodrigues Conti
    Citation: The Journal of Headache and Pain 2025 26:98
    Content type: Research Published on:

  24. S100A4 participates in inflammation and immune reactions in the central nervous system and is involved in the pathogenesis of multiple neurological disorders. It can affect the functions of astrocytes, microgl...

    Authors: Tao Xue, Yu Song, Jie Zhao, Guiyong Fan and Zhiyuan Liu
    Citation: The Journal of Headache and Pain 2025 26:97
    Content type: Research Published on:

  25. In adults, intravenous (IV) dihydroergotamine (DHE) has been shown to be effective at improving medium term outcomes in patients with chronic headache disorders. The IV formulation is utilized given its superi...

    Authors: Sara Pavitt, Cynthia Morris, Lauren Shin, Andrew Jones, Beata Vayngortin, Natalia Zorrilla, Chengshi Jin, Isabel Allen and Amy A. Gelfand
    Citation: The Journal of Headache and Pain 2025 26:93
    Content type: Research Published on:

  26. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal-dominantly inherited cerebral small-vessel disease (SVD). CADASIL has diverse clinical featu...

    Authors: Parasta Heidari, Motahareh Taghizadeh and Omid Vakili
    Citation: The Journal of Headache and Pain 2025 26:96
    Content type: Review Published on:

  27. Calcitonin Gene-Related Peptide (CGRP) is involved in migraine pain signaling, and blockage hereof is effective in migraine treatment. Headache in idiopathic intracranial hypertension (IIH) is often migraine-l...

    Authors: Nadja Skadkær Hansen, Johanne Juhl Korsbaek, Lasse Kristoffer Bak, Niklas Rye Jørgensen, Dagmar Beier and Rigmor Højland Jensen
    Citation: The Journal of Headache and Pain 2025 26:95
    Content type: Research Published on:

  29. Migraine has been linked to a heightened risk of cardiovascular disease, and acute treatment drugs, such as triptans, might increase this risk. This study aimed to determine whether the elevated cardiovascular...

    Authors: Ying Huang, Wen Yan, Yifan Jia, Qingfang Xie, Yuexiu Lei, Zepeng Chen, Yanjie Zhou and Zheman Xiao
    Citation: The Journal of Headache and Pain 2025 26:92
    Content type: Research Published on:

  30. Cortical spreading depression (CSD) is a wave of neuronal and glial depolarization followed by suppressed neural activity, thought to underlie migraine aura. While Calcitonin Gene-Related Peptide (CGRP) is wel...

    Authors: Agustin Melo-Carrillo
    Citation: The Journal of Headache and Pain 2025 26:91
    Content type: Comment Published on:

    The original article was published in The Journal of Headache and Pain 2025 26:90

  32. The diagnosis of reversible cerebral vasoconstriction syndrome (RCVS) is challenging due to its varied clinical manifestations and imaging findings. While it typically presents with a sudden, severe thundercla...

    Authors: Seung Ae Kim, Eung Yeop Kim, Shuu-Jiun Wang and Mi Ji Lee
    Citation: The Journal of Headache and Pain 2025 26:89
    Content type: Review Published on:

  33. Calcitonin gene related peptide (CGRP) pathway targeting therapies have proven efficacy, safety and tolerability. However, CGRP is also involved in immune responses, and reports of an increased risk of infecti...

    Authors: Marcin Straburzyński, Daria Kopyt, Karol Marschollek, Bartłomiej Błaszczyk, Ewa Kuca-Warnawin, Weronika Kurowska, Błażej Misiak, Kuan-Po Peng, Marta Waliszewska-Prosół and Arne May
    Citation: The Journal of Headache and Pain 2025 26:88
    Content type: Review Published on:

  35. Soluble urokinase-plasminogen activator receptor (suPAR) is a biomarker of systemic inflammation and elevated in plasma of individuals with migraine with aura. As inflammatory cytokines can upregulate calciton...

    Authors: William K. Karlsson, Rune H. Christensen, Haidar M. Al-Khazali, Thomas Kallemose, Baker N. Jawad, Ove Andersen, Messoud Ashina and Håkan Ashina
    Citation: The Journal of Headache and Pain 2025 26:86
    Content type: Research Published on:

  36. Migraine is a common neurovascular disorder that remains currently untreated in half of the patients. One third of migraine patients experience aura, which is associated with the development of cortical spread...

    Authors: Flavia Brugia, Konstantin Ivanov, Auni Aroviita, Raisa Giniatullina, Marko Lehtonen, Tarja Malm, Juha Savinainen, Rashid Giniatullin and Adriana Della Pietra
    Citation: The Journal of Headache and Pain 2025 26:85
    Content type: Research Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2025 26:111

  37. Migraine affects over 1 billion people worldwide and is a leading cause of disability. Targeting the cannabinoid system offers a promising approach for pain and migraine relief. This study evaluated a novel mo...

    Authors: Elizaveta Mangutov, Yaseen Awad-Igbaria, Kendra Siegersma, Francois Gastambide, Ayodeji A. Asuni and Amynah A. A. Pradhan
    Citation: The Journal of Headache and Pain 2025 26:84
    Content type: Research Published on:

  38. Rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, is the first drug within its class approved for both acute and preventive treatment of migraine. This study examines its uptake i...

    Authors: Lanfranco Pellesi, Thien Phu Do, Martin Thomsen Ernst, Jesper Hallas and Anton Pottegård
    Citation: The Journal of Headache and Pain 2025 26:83
    Content type: Research Published on:

  39. Endometriosis affects women of reproductive age. Increasing attention is being given to the characterization of comorbidities in endometriosis to enhance clinical phenotyping. Among these comorbidities, migrai...

    Authors: Giorgia Elisabeth Colombo, Sofia Makieva, Edgardo Somigliana, Georgios Schoretsanitis, Brigitte Leeners, Christian Polli, Noemi Salmeri, Dimitrios Rafail Kalaitzopoulos and Paola Vigano’
    Citation: The Journal of Headache and Pain 2025 26:82
    Content type: Review Published on:

  41. Migraine is a common primary headache disorder with different treatment modalities emerging as ultrasound guided peripheral nerve blocks. We compared the efficacy and safety of ultrasound guided bilateral sphe...

    Authors: Nourhan Abdelmohsen Taha, Mai Fathy, Ahmed Elsadek, Tamer Hussein Emara, Sherien Mohamed Farag, Ramez Reda Moustafa and Mohamad Osama Abdulghani
    Citation: The Journal of Headache and Pain 2025 26:80
    Content type: Research Published on:

  42. Calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) are key pathogenic drivers of migraine. While CGRP has become the target of several mechanism-based th...

    Authors: Mohammad Al-Mahdi Al-Karagholi, Zixuan Alice Zhuang, Signe Beich, Håkan Ashina and Messoud Ashina
    Citation: The Journal of Headache and Pain 2025 26:79
    Content type: Research Published on:

  43. Migraine significantly impairs quality of life, reduces workplace productivity, and imposes a substantial socio-economic burden. The severity of migraine correlates with its impact on quality of life and healt...

    Authors: Mira Pauline Fitzek, Lucas Hendrik Overeem, Marlene Ulrich, Ja Bin Hong, Carolin Luisa Hoehne, Kristin Sophie Lange, Yones Salim, Uwe Reuter and Bianca Raffaelli
    Citation: The Journal of Headache and Pain 2025 26:78
    Content type: Research Published on:

  44. Migraine is a primary headache disorder, with a prevalence estimated at approximately 15% globally. According to the International Classification of Headache Disorders, 3rd edition (ICHD3), there are three sig...

    Authors: Olga Grodzka, Ketevan Dzagoevi, Tayla Rees, Goncalo Cabral, Piotr Chądzyński, Stefano Di Antonio, Patryk Sochań, Antoinette MaassenVanDenBrink and Christian Lampl
    Citation: The Journal of Headache and Pain 2025 26:77
    Content type: Review Published on:

  45. This study aims to improve the understanding of the patient journey via the perspectives of patients with migraine.

    Authors: Anne Duburcq, Manon Molins, Sabine Debremaeker, Julie Joie, Luna Lopes, Camille Nevoret and Olivia Begasse de Dhaem
    Citation: The Journal of Headache and Pain 2025 26:76
    Content type: Research Published on:

  46. The epidural blood patch (EBP) is the treatment of choice for spontaneous intracranial hypotension (SIH). Studies have shown that targeted EBP is more effective than blind EBP. Additionally, a greater volume o...

    Authors: Woo-Seok Ha, JaeWook Jeong, Seungwon Song, Jungyon Yum, Soomi Cho, Hee Jung Kim and Min Kyung Chu
    Citation: The Journal of Headache and Pain 2025 26:75
    Content type: Research Published on:

  47. Clinical observational evidence suggests a close association between Trigeminal Neuralgia (TN) and Mental disorders (MDs). However, the causal relationship between the two remains unclear. This study aims to o...

    Authors: Jianke Wang, Mingxiao Li, Ze Zhang, Yu Duan, Ziyi Zhang, Hanlin Liu, Ke Yang and Jiang Liu
    Citation: The Journal of Headache and Pain 2025 26:74
    Content type: Research Published on:

  48. According to the International Classification of Headache Disorders, 3rd edition (ICHD-3), headache disorders can be divided into two main groups: primary, which are not caused by any other disease, and second...

    Authors: Olga Grodzka, Wiktor Łagowski, Ceren Eyileten and Izabela Domitrz
    Citation: The Journal of Headache and Pain 2025 26:73
    Content type: Review Published on:

  49. The optimal management of migraine involves care strategies that reflect what matters most to patients. This usually involves an assessment of treatment efficacy with respect to headache reduction, safety of p...

    Authors: Lakshini Gunasekera, Jason C. Ray, Neha Kaul, Helmut Butzkueven, Elspeth Hutton and Terence J. O’Brien
    Citation: The Journal of Headache and Pain 2025 26:72
    Content type: Review Published on:
Submit manuscript

Official journal of

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 7.3
    5-year Journal Impact Factor: 7.7
    Source Normalized Impact per Paper (SNIP): 1.830
    SCImago Journal Rank (SJR): 1.791

    Speed 2024
    Submission to first editorial decision (median days): 1
    Submission to acceptance (median days): 45

    Usage 2024
    Downloads: 2,713,192
    Altmetric mentions: 1,825

  • ISSN: 1129-2377 (electronic)
  • ISSN: 1129-2369 (print)

Related reading

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us